All In Biotech

Drug Trial Radar · NCT07450547

Phase 2 Study to Assess the Safety and Efficacy of ANG003

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

113

Planned (sponsor's estimate)

Start

Apr 24, 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Anagram Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

Conditions

  • Exocrine Pancreatic Insufficiency (EPI)
  • Cystic Fibrosis (CF)

Interventions

  • ANG003 Dose ADrug

    160,000 u\* lipase, 105,000 u\* protease, and 11,600 u\* amylase per dose (\*units are comparable to United States Pharmacopeiea \[USP\])

  • ANG003 Dose BDrug

    240,000 u\* lipase, 105,000 u\* protease, and 11,600 u\* amylase per dose (\*units are comparable to United States Pharmacopeiea \[USP\])

  • CreonDrug

    The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory valuesTime frame: From Visit 1 to Visit 5, anticipated average 80 days
  2. Coefficient of Fat Absorption (CFA)Time frame: Period A (baseline) and Period B 72 hour CFA collection

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Long Beach Memorial Medical Center

    Long Beach, California · Recruiting

  • Center for Cystic Fibrosis at Keck Medical Center of USC

    Los Angeles, California · Recruiting

  • National Jewish Health

    Denver, Colorado · Recruiting

  • University of Florida

    Gainesville, Florida · Not yet recruiting

  • Central Florida Pulmonary Group

    Orlando, Florida · Not yet recruiting

  • Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center

    Atlanta, Georgia · Recruiting

  • The Cystic Fibrosis Institute

    Glenview, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Not yet recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • MaineHealth Pediatric Specialty Care

    Portland, Maine · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Boston Children's Hospita

    Boston, Massachusetts · Recruiting

  • University of Michigan, Michigan Medicine

    Ann Arbor, Michigan · Recruiting

  • Wayne State University Harper University Hospital

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Rutgers - Robert Wood Johnson Medical School

    New Brunswick, New Jersey · Recruiting

  • New York Medical College at Westchester Medical Center

    Valhalla, New York · Not yet recruiting

  • Children's Hospital Medical Center of Akron

    Akron, Ohio · Recruiting

  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Nationwide Children's Hospital, Columbus

    Columbus, Ohio · Recruiting

  • Toledo Children's Hospital

    Toledo, Ohio · Recruiting

  • Hershey Medical Center Pennsylvania State University

    Hershey, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • University of Texas Southwestern / Children's Health

    Dallas, Texas · Recruiting

  • Adult Cystic Fibrosis Center at the University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.